Key facts
- This page summarizes Stanislav Glezer's Form 4 filing for Inogen Inc (INGN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2022, 19:54.
Stanislav Glezer - 01 Mar 2022 Form 4 Insider Report for Inogen Inc (INGN)
- Reporting relationship
- EVP, Chief Medical Officer
- Issuer ticker
- INGN
- Reported as of
- 01 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2022, 19:54:47 UTC
- Prior SEC filing
- 11 Aug 2021
- Next SEC filing
- 12 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leslyn Cicekli, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stanislav Glezer filed Form 4 for Inogen Inc (INGN) on 03 Mar 2022.
Change
- Previous filing in this sequence was filed on 11 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INGN
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +11,360
- Change %
- Price
- $0.000000
- Shares after
- 11,360
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,360
- Exercise price
- Footnotes
- F1, F2
INGN
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +11,360
- Change %
- Price
- $0.000000
- Shares after
- 11,360
- Date
- 01 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,360
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Inogen common stock.
Footnote F2
Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on March 1, 2023, and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the vesting commencement date.
Footnote F3
Subject to the reporting person's continued service, 1/3rd of the restricted stock units shall vest on December 1, 2022, and 1/3rd of the restricted stock units shall vest every year thereafter on the same day of the year as the vesting commencement date.